High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetes

References

• Sharma S, Rayman G. Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN). Front Endocrinol. 2023 May 18;14:1165505. doi: 10.3389/fendo.2023.1165505
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136–154. doi: 10.2337/dc16-2042
   PubMed Web of Science ®Google Scholar
• Williams TJ. Eotaxin-1 (CCL11). Front Immunol. 2015 Feb 24;6:84. doi: 10.3389/fimmu.2015.00084
   PubMed Web of Science ®Google Scholar
• Huber AK, Giles DA, Segal BM, et al. An emerging role for eotaxins in neurodegenerative disease. Clin Immunol. 2018 Apr;189:29–33. doi: 10.1016/j.clim.2016.09.010
   PubMed Web of Science ®Google Scholar
• Parajuli B, Horiuchi H, Mizuno T, et al. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015 Dec;63(12):2274–2284. doi: 10.1002/glia.22892
   PubMed Web of Science ®Google Scholar
• Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011 Aug 31;477(7362):90–94. doi: 10.1038/nature10357
   PubMed Web of Science ®Google Scholar
• Tejera-Alhambra M, Casrouge A, de Andrés C, et al. Plasma biomarkers discriminate clinical forms of multiple sclerosis. PLOS ONE. 2015 Jun 3;10(6):e0128952. doi: 10.1371/journal.pone.0128952
   PubMed Web of Science ®Google Scholar
• Lalli MA, Bettcher BM, Arcila ML, et al. Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer’s disease. Mol Psychiatry. 2015 Nov;20(11):1294–1300. doi: 10.1038/mp.2015.131
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci. 2013 Mar;263(2):159–165. doi: 10.1007/s00406-012-0327-6
   PubMed Web of Science ®Google Scholar
• García-Marchena N, Barrera M, Mestre-Pintó JI, et al. Inflammatory mediators and dual depression: potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders. PLOS ONE. 2019 Mar 14;14(3):e0213791. doi: 10.1371/journal.pone.0213791
   PubMed Web of Science ®Google Scholar
• Hong S, Lee EE, Martin AS, et al. Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophr Res. 2017 Mar;181:63–69. doi: 10.1016/j.schres.2016.09.019
   PubMed Web of Science ®Google Scholar
• Mantovani A, Gray PA, Van Damme J, et al. Macrophage-derived chemokine (MDC). J Leukocyte Biol. 2000 Sep;68(3):400–404. doi: 10.1189/jlb.68.3.400
   PubMed Web of Science ®Google Scholar
• Aso Y, Kase M, Sagara M, et al. Teneligliptin, a DPP-4 Inhibitor, decreases plasma levels of inflammatory chemokines during a standard meal test in patients with type 2 diabetes. Am J Med Sci. 2020 Sep;360(3):261–267. doi: 10.1016/j.amjms.2020.05.005
   PubMed Web of Science ®Google Scholar
• Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011;18(11):924–938. doi: 10.5551/jat.7716
   PubMed Web of Science ®Google Scholar
• Kase M, Iijima T, Niitani T, et al. Relationship between reduced heart rate variability and increased arterial stiffness evaluated by the cardio-ankle vascular index in people with type 2 diabetes. Diabetol Int. 2022 Sep 29;14(1):94–102. doi: 10.1007/s13340-022-00604-y
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Wu H, Xydakis AM, et al. Eotaxin and obesity. J Clin Endocrinol Metab. 2006 Jan;91(1):256–261. doi: 10.1210/jc.2005-1280
   PubMed Web of Science ®Google Scholar
• Araújo LS, Torquato BGS, da Silva CA, et al. Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol. 2020 Jul 28;21(1):308. doi: 10.1186/s12882-020-01960-0
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Chemokines, chemokine receptors and allergy. Int Arch Allergy Immunol. 2001 Apr;124(4):423–431. doi: 10.1159/000053777
   PubMed Web of Science ®Google Scholar
• Jahnz-Rozyk K, Targowski T, Paluchowska E, et al. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy. 2005 May;60(5):685–688. doi: 10.1111/j.1398-9995.2005.00774.x
   PubMed Web of Science ®Google Scholar
• Spallone V, Ziegler D, Freeman R, et al. Toronto consensus panel on diabetic neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639–653. doi: 10.1002/dmrr.1239
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Albers JW, Andersen H, et al. Toronto expert panel on diabetic neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620–628. doi: 10.1002/dmrr.1226
   PubMed Web of Science ®Google Scholar
• Ivanovska M, Abdi Z, Murdjeva M, et al. CCL-11 or eotaxin-1: an immune marker for ageing and accelerated ageing in neuro-psychiatric disorders. Pharmaceuticals (Basel). 2020 Sep 2;13(9):230. doi: 10.3390/ph13090230
   PubMedGoogle Scholar
• Hyllienmark L, Alstrand N, Jonsson B, et al. Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care. 2013 Oct;36(10):3187–3194. doi: 10.2337/dc12-2226
   PubMed Web of Science ®Google Scholar
• Popescu S, Timar B, Baderca F, et al. Age as an independent factor for the development of neuropathy in diabetic patients. Age as an independent factor for the development of neuropathy in diabetic patients. Clin Interv Aging. 2016 Mar 15;11:313–318. doi: 10.2147/CIA.S97295
   PubMed Web of Science ®Google Scholar
• Maalmi H, Strom A, Petrera A, et al. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia. 2023 Mar;66(3):579–589. doi: 10.1007/s00125-022-05846-8
   PubMed Web of Science ®Google Scholar
• Büttner R, Schulz A, Reuter M, et al. Inflammaging impairs peripheral nerve maintenance and regeneration. Aging Cell. 2018 Dec;17(6):e12833. doi: 10.1111/acel.12833
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285–2293. doi: 10.2337/dc10-1303
   PubMed Web of Science ®Google Scholar